NeuroSense reports first nine months EPS (48c) vs. (55c) last year

Operating expenses for the nine months ended September 30, 2024 and 2023 were $8.1M and $9M, respectively. “The completion of the 18-month Phase 2b PARADIGM study was a major milestone for NeuroSense (NRSN). The results highlight PrimeC’s potential impact on slowing disease progression and survival benefits in people living with ALS. Furthermore, the positive feedback from a Type C meeting with the FDA on the pivotal study design has the Company on track to commence a Phase 3 study in mid-2025. In parallel, the Company is taking steps toward early commercialization in Canada, with an anticipated potential launch in 2026, bringing us closer to delivering a much-needed solution to the ALS community,” stated Alon Ben-Noon, CEO of NeuroSense.